• Clinically Safe Drugs and CRISPR Repair Choice

  2026-10-07

  A 2025 Nature Communications study used a large repurposing screen in human induced pluripotent stem cells to identify clinically approved drugs that alter the balance among NHEJ, MMEJ, and HDR after CRISPR-induced DNA breaks. Its most notable findings include drug-linked repair modulation, roles for ESR2 and AOX1, and a reported 4.6-fold mean increase in HDR when ESR2 silencing was combined with NHEJ inhibition.

• E-64 Beyond Potency: Reading Cathepsin Evidence

  2026-10-07

  E-64 is a L-trans-epoxysuccinyl peptide used to study cysteine protease inhibition. This evidence-focused analysis explains its mechanism, interprets a negative in vivo cathepsin study, and defines the limits of translating biochemical potency into disease effects.

• Protein A/G Beads in TNBC Mechanism Research

  2026-10-06

  This overview examines how the reported IGF2BP3–FZD1/7 mechanism may be investigated conceptually with antibody-based affinity capture, including Protein A/G Magnetic Beads. It distinguishes the 2025 preclinical findings from broader interpretation, explains evidence strengths and limitations, and clarifies that the supplied study does not establish use of APExBIO beads or clinical therapeutic benefit.

• EGCG Hydrogel Microspheres for Disc Degeneration

  2026-10-06

  The reference study introduces an elastic dual-network hydrogel microsphere that combines EGCG-containing metal-phenolic networks with stimulus-responsive delivery of miR-155 and chitooligosaccharide. In cell and animal models of intervertebral disc degeneration, the platform was reported to reduce inflammatory stress, protect nucleus pulposus cells, and support tissue-function recovery, although its translational value remains limited by incomplete clinical and quantitative evidence.

• CBEmax mRNA: Fidelity Before Translation

  2026-10-05

  A source-grounded thought-leadership analysis of cytosine base-editing fidelity, the limits of extrapolating BE4 mouse-embryo findings to R1044, and a strategic framework for translational validation.

• LY294002 and the SPP1–Macrophage PI3K Axis

  2026-10-05

  LY294002 is more than a generic PI3K/Akt/mTOR signaling pathway inhibitor. This article examines how it can help interrogate SPP1-driven macrophage biology in ESCC while clarifying selectivity, off-target effects, and the limits of pharmacological evidence.

• Deoxycholic Acid Sodium Salt in NSCLC Research

  2026-10-04

  Explore how Deoxycholic acid sodium salt should be interpreted alongside research on SNORA38B, GAB2/AKT/mTOR signaling, and immune checkpoint blockade in NSCLC. This evidence-focused analysis separates product identity, assay context, and therapeutic causality.

• Zilovertamab in ROR1 and DON Liver Research

  2026-10-03

  The supplied DON study reports a mechanistic relationship between excessive PINK1/Parkin-mediated mitophagy, mitochondrial injury, and suppression of the p62–Keap1–Nrf2 defense pathway in mouse and AML-12 liver models. Zilovertamab offers a conceptual tool for asking whether ROR1 biology intersects with this injury network, but the supplied evidence does not establish ROR1 involvement in DON hepatotoxicity or validate Anti-ROR1 Antibody as a treatment or research reagent for that model.

• Merimepodib (VX-497): Designing Better IMPDH Assays

  2026-10-02

  Merimepodib (VX-497) is a selective IMPDH inhibitor whose effects connect guanine nucleotide metabolism with antiviral, immunology, and cancer research. This article explains how cell context, rescue experiments, and orthogonal validation can turn IMPDH inhibition into a more rigorous assay strategy.

• HDAC3–TPM3 K141 Control of Vasoconstriction

  2026-10-01

  This reference study identifies HDAC3-mediated de-2-hydroxyisobutyrylation of tropomyosin 3 at Lys141 as a regulatory mechanism linking phenylephrine signaling to abnormal vascular smooth muscle contraction. Its combination of biochemical, vascular tension, computational, and mutation-based experiments suggests that TPM3 2-hydroxyisobutyrylation may be a useful mechanistic and therapeutic target in hypertensive vascular dysfunction, although clinical translation remains unproven.

• Potassium Phosphate Monobasic for Assay Workflows

  2026-10-01

  Potassium phosphate monobasic provides a practical KH2PO4 foundation for reproducible enzyme assays, cell-compatible buffer screening, and post-reconstitution testing of nucleic acid nanoparticles. This guide connects precise buffer preparation with drying-study design while emphasizing pH verification, solvent compatibility, and prompt use of aqueous solutions.

• GW 4869: Exosome Release and Ceramide Workflows

  2026-09-30

  GW 4869 connects neutral sphingomyelinase activity with exosome-dependent cell communication, making it useful for separating donor-cell vesicle release from recipient-cell injury. This practical guide applies the compound to lupus nephritis-inspired assays while outlining dose planning, controls, normalization, and troubleshooting.

• DiI (DiIC18(3)) Membrane Probe Guide

  2026-09-30

  DiI (DiIC18(3)) provides orange-red labeling of lipid bilayers for membrane visualization, neuronal tracing, migration studies, and related live or fixed-sample workflows. It is not water-soluble and should not be selected for aqueous-only staining or organelle-specific labeling without a membrane-based rationale.

• Reserpine (N1867): Practical Lab Protocol Guide

  2026-09-29

  Reserpine (SKU N1867) provides a high-purity research compound for neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide addresses identity checks, DMSO-based preparation, storage, and troubleshooting; the material is for research use only and is not intended for diagnostic, therapeutic, or medical applications.

• PRKX Stabilizes PD-L1 in Gastric Cancer

  2026-09-29

  A 2026 study identifies PRKX as a regulator of an immunosuppressive gastric cancer subtype, linking PRKX phosphorylation of PD-L1 to YWHAE recruitment, reduced ubiquitination, and immune exhaustion. The work combines single-cell profiling, mechanistic experiments, patient biomarker analysis, and lipid nanoparticle delivery of PRKX-targeting siRNA to explain resistance to anti-PD-1 therapy.

8629 records 1/576 page Next 12345 下5页 Last page